Diagnostics Solutions News Today

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and...

1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts: Investors: Adam Reiffe, Sr....

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organicQ1 GAAP and...

/PRNewswire/ -- The "Point of Care (POC) Analyzers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key...

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4...

In a report released yesterday, Derik De Bruin from Bank of America Securities reiterated a Buy rating on Stevanato Group (STVN – Research...

Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™...

BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and... | May 4, 2023

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration...

The firm said the ThinPrep is among the most common Pap test collection vials in the US and the new approval will expand access to the Onclarity HPV assay.